Uncategorized

Regeneron ends eye disease study due to antibody’s safety profile

Published

on

The discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen for melanoma.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version